Thermo Fisher Scientific Expands its Global Biologics and Steriles Manufacturing Capabilities in China
ORC International’s report “Implications of Inaccurate Forecasting on Biologics Drug Substance Manufacturing” explores the causes, consequences, and potential solutions to forecasting challenges specifically related to biopharmaceutical drug substance manufacturing. This analysis provides further insight and perspective on the key themes that emerge from the report and offers additional solutions to companies to better prepare for the inevitable forecast inaccuracies for biopharmaceuticals.
Patti Seymour, Senior Consultant
Tom Ransohoff, Principal Consultant
Dawn M. Ecker, Consultant
Howard H. Levine, President and CEO